Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Societe Francophone de Greffe de Moelle et de Therapie Cel

Affiliation auteurs!!!! Error affiliation !!!!
TitreReduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Societe Francophone de Greffe de Moelle et de Therapie Cel
Type de publicationJournal Article
Year of Publication2017
AuteursLe Bourgeois A., Labopin M., Blaise D., Ceballos P., Vigouroux S., R. de latour P, Marcais A., Bulabois C.E, Bay J.O, Chantepie S., Deconinck E., Daguindau E., Contentin N., Yakoub-Agha I., Cornillon J., Mercier M., Turlure P., Charbonnier A., Rorhlich P.S, N'Guyen S., Maillard N., Marchand T., Mohty M., Chevallier P., Moe SFrancophon
JournalANNALS OF ONCOLOGY
Volume28
Pagination2191-2198
Date PublishedSEP
Type of ArticleArticle
ISSN0923-7534
Mots-clésallogeneic stem-cell transplantation, busulfan, Conditioning regimen, non-Hodgkin lymphoma
Résumé

{Background: Fludarabine/busulfan-based conditioning regimens are widely used to perform allogeneic stem-cell transplantation (allo-SCT) in high-risk non-Hodgkin lymphoma (NHL) patients. The impact of the dose intensity of busulfan on outcomes has not been reported yet. Patients and methods: This was a retrospective with the aim to compare the outcomes of NHL patients who received before allo-SCT a fludarabine/busulfan conditioning regimen, either of reduced intensity (FB2, 2 days of busulfan at 4 mg/kg/day oral or 3.2 mg/kg/day i.v.) (n = 277) or at a myeloablative reduced-toxicity dose (FB3/FB4, 3 or 4 days of busulfan at 4 mg/kg/day oral or 3.2 mg/kg/day i.v.) (n = 101). Results: In univariate analysis, the 2-year overall survival (FB2 66.5% versus 60.3%
DOI10.1093/annonc/mdx274